280 related articles for article (PubMed ID: 31897779)
1. Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.
Salgado TM; Quinn CS; Krumbach EK; Wenceslao I; Gonzalez M; Reed HL; Syverson JG; Etz RS; Vangipuram K; Barker MR; Henry NL; Farris KB; Hertz DL
Support Care Cancer; 2020 Sep; 28(9):4163-4172. PubMed ID: 31897779
[TBL] [Abstract][Full Text] [Related]
2. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.
Salgado TM; Liu J; Reed HL; Quinn CS; Syverson JG; Le-Rademacher J; Lopez CL; Beutler AS; Loprinzi CL; Vangipuram K; Smith EML; Henry NL; Farris KB; Hertz DL
Breast; 2020 Jun; 51():21-28. PubMed ID: 32193049
[TBL] [Abstract][Full Text] [Related]
3. Lived experiences and support needs of women who developed chemotherapy-induced peripheral neuropathy following treatment for breast and ovarian cancer.
Tanay MA; Armes J
Eur J Cancer Care (Engl); 2019 May; 28(3):e13011. PubMed ID: 30790382
[TBL] [Abstract][Full Text] [Related]
4. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
6. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
[TBL] [Abstract][Full Text] [Related]
7. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
Speck RM; DeMichele A; Farrar JT; Hennessy S; Mao JJ; Stineman MG; Barg FK
Support Care Cancer; 2012 Oct; 20(10):2433-9. PubMed ID: 22231480
[TBL] [Abstract][Full Text] [Related]
8. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
11. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
[TBL] [Abstract][Full Text] [Related]
12. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
Mehrotra S; Sharma MR; Gray E; Wu K; Barry WT; Hudis C; Winer EP; Lyss AP; Toppmeyer DL; Moreno-Aspitia A; Lad TE; Valasco M; Overmoyer B; Rugo H; Ratain MJ; Gobburu JV
AAPS J; 2017 Sep; 19(5):1411-1423. PubMed ID: 28620884
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
Jin L; Zhang Y; Yang W
Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel.
Brady BL; Lucci M; Wilson K; Fox KM; Wojtynek J; Cooper C; Varker H; Chebili CL; Dokubo I
Am J Manag Care; 2021 Jan; 27(1 Spec. No.):SP37-SP43. PubMed ID: 33395243
[TBL] [Abstract][Full Text] [Related]
16. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
Greenwald MK; Ruterbusch JJ; Beebe-Dimmer JL; Simon MS; Albrecht TL; Schwartz AG
Cancer; 2019 Jan; 125(2):269-277. PubMed ID: 30387871
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.
Reyes-Gibby CC; Morrow PK; Buzdar A; Shete S
J Pain; 2009 Nov; 10(11):1146-50. PubMed ID: 19595634
[TBL] [Abstract][Full Text] [Related]
18. Exploring Clinicians' Perspectives of Barriers to Chemotherapy-Induced Peripheral Neuropathy Assessment and Management in Oncology Practice: A Qualitative Analysis of Semi-structured Interviews.
Knoerl R; Wallar J; Fox E; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
Cancer Nurs; 2023 Mar-Apr 01; 46(2):103-110. PubMed ID: 35283473
[TBL] [Abstract][Full Text] [Related]
19. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
[TBL] [Abstract][Full Text] [Related]
20. Clinician and patient experiences when providing and receiving information and support for managing chemotherapy-induced peripheral neuropathy: A qualitative multiple methods study.
Tanay MAL; Robert G; Rafferty AM; Moss-Morris R; Armes J
Eur J Cancer Care (Engl); 2022 Jan; 31(1):e13517. PubMed ID: 34643016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
